1. Endothelial α 1 -adrenergic receptor activation improves cardiac function in septic mice via PKC-ERK/p38MAPK signaling pathway.
- Author
-
Tian T, Yu Q, Yang D, Zhang X, Zhang C, Li J, Luo T, Zhang K, Lv X, Wang Y, Wang H, and Li H
- Subjects
- Animals, Humans, Male, Mice, Adrenergic alpha-1 Receptor Agonists pharmacology, Adrenergic alpha-1 Receptor Agonists therapeutic use, MAP Kinase Signaling System drug effects, Cardiomyopathies drug therapy, Cardiomyopathies etiology, Cardiomyopathies metabolism, Signal Transduction drug effects, Cells, Cultured, Sepsis drug therapy, Sepsis metabolism, Receptors, Adrenergic, alpha-1 metabolism, Protein Kinase C metabolism, p38 Mitogen-Activated Protein Kinases metabolism, Phenylephrine pharmacology, Mice, Inbred C57BL, Endothelial Cells drug effects, Endothelial Cells metabolism
- Abstract
Cardiomyopathy is particularly common in septic patients. Our previous studies have shown that activation of the alpha 1 adrenergic receptor (α
1 -AR) on cardiomyocytes inhibits sepsis-induced myocardial dysfunction. However, the role of cardiac endothelial α1 -AR in septic cardiomyopathy has not been determined. Here, we identified α1 -AR expression in mouse and human endothelial cells and showed that activation of α1 -AR with phenylephrine (PE) improved cardiac function and survival by preventing cardiac endothelial injury in septic mice. Mechanistically, activating α1 -AR with PE decreased the expression of ICAM-1, VCAM-1, iNOS, E-selectin, and p-p38MAPK, while promoting PKC and ERK1/2 phosphorylation in LPS-treated endothelial cells. These effects were abolished by a PKC inhibitor or α1 -AR antagonist. PE also reduced p65 nuclear translocation, but this suppression is not blocked by PKC inhibition. Treatment with U0126 (a specific ERK1/2 inhibitor) reversed the effects of PE on p38MAPK phosphorylation. Our results demonstrate that cardiac endothelial α1 -AR activation prevents sepsis-induced myocardial dysfunction in mice by inhibiting the endothelial injury via PKC-ERK/p38MAPK signaling pathway and a PKC-independent inhibition of p65 nuclear translocation. These findings offer a new perspective for septic patients with cardiac dysfunction by inhibiting cardiac endothelial cell injury through α1 -AR activation., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF